Russia's NSCLC market set to grow to $163 million in 2015

The Russian market for non-small-cell lung cancer (NSCLC) therapies will grow 3% annually from 2010 to reach a value of $163 million in 2015, according to the health care advisory firm Decision Resources Emerging Markets report, Non-Small-Cell Lung Cancer in Russia, noting that an increase in the incident population, gradually increasing use of higher-priced chemotherapies and the introduction of several premium-priced agents will promote this growth.

The incidence of non-small-cell lung cancer in Russia is the highest among the BRIC (Brazil, Russia, India and China) markets and is comparable to that of the UK and the USA. Increasing risk of non-small-cell lung cancer due to the growing smoking prevalence in men, in conjunction with an aging population, will drive an increase in incident NSCLC cases in Russia.

Russia’s NSCLC therapy market is characterized by the growing incident population, gradually increasing use of higher-priced chemotherapies and the introduction of several premium-priced agents. Reimbursement policies in both the public and private sectors are a major factor influencing expenditure on NSCLC treatments in the country, the report notes.